Summary
Intuitive Surgical Inc. reported strong performance in the first quarter of 2021, with total revenue increasing by 18% year-over-year to $1.29 billion. This growth was primarily driven by a significant 30% increase in systems revenue and a 14% rise in instruments and accessories revenue, indicating a robust recovery and adoption of robotic-assisted procedures post-initial COVID-19 impacts. The company also saw a notable increase in da Vinci Surgical System placements, up 26% year-over-year, and continued expansion of its installed base. Despite ongoing uncertainties related to the COVID-19 pandemic and supply chain challenges, the company's financial position remains strong with substantial cash reserves and positive operating cash flow.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $1.29B |
| Cost of Revenue | $389.50M |
| Gross Profit | $902.60M |
| R&D Expenses | $159.80M |
| SG&A Expenses | $326.00M |
| Operating Expenses | $485.80M |
| Operating Income | $416.80M |
| Net Income | $426.30M |
| EPS (Basic) | $1.20 |
| EPS (Diluted) | $1.17 |
| Shares Outstanding (Basic) | 354.20M |
| Shares Outstanding (Diluted) | 364.00M |
Key Highlights
- 1Total revenue grew 18% to $1.29 billion in Q1 2021 compared to $1.10 billion in Q1 2020.
- 2Systems revenue saw a substantial increase of 30%, reaching $369 million, driven by a 26% rise in da Vinci Surgical System shipments.
- 3Instruments and accessories revenue increased by 14% to $706 million, reflecting increased procedure volume.
- 4Total da Vinci procedures performed increased by 16% year-over-year, indicating a strong recovery in surgical activity.
- 5The company's gross profit margin improved to 69.9% from 67.1% in the prior year period.
- 6Operating income saw a significant increase of 47%, reaching $417 million.
- 7The installed base of da Vinci Surgical Systems grew by 8% to approximately 6,142 systems as of March 31, 2021.
Frequently Asked Questions
Revenue growth was primarily driven by a substantial 30% increase in systems revenue, supported by a 26% increase in da Vinci Surgical System placements, and a 14% increase in instruments and accessories revenue, reflecting higher procedure volumes.
The company acknowledges the ongoing impact of the COVID-19 pandemic on hospital resources and procedure deferrals. However, it also highlights a strong recovery in procedures in early 2021 and robust system demand. The company's priorities include ensuring health and safety, supporting customers, securing its workforce, and continuing investment in development programs while managing expenses.
Intuitive Surgical maintains a strong financial position with $7.23 billion in cash, cash equivalents, and investments as of March 31, 2021. The company generated strong operating cash flow of $477.6 million in the first quarter of 2021 and anticipates being able to fund future growth through its operations.
The filing mentions ongoing product liability litigation and patent litigation with Ethicon. While the company is defending these claims, the ultimate outcome and potential financial impact remain uncertain. The company is also subject to various other legal proceedings and regulatory requirements common in the medical device industry.